Table 2.
The Convergent Validity of the Benefits-Risks of Complementary Therapy (CT) Use Scale
| Parameter Estimation | Convergent Validity | ||||||
|---|---|---|---|---|---|---|---|
| Dimension/Item | Estimate | SE | CR | p | Standardized Coefficient | CR | AVE |
| F1 Patient’s medical condition | .90 | .69 | |||||
| Item 1 Overall health status | 1.00 | .83 | |||||
| Item 2 Diabetes condition details | 1.06 | 0.06 | 19.72 | <.001 | .91 | ||
| Item 3 Laboratory data | 0.95 | 0.06 | 16.73 | <.001 | .83 | ||
| Item 4 Diabetes-related complications | 0.83 | 0.06 | 14.55 | <.001 | .75 | ||
| F2 Benefit-risk assessment of CTs | .85 | .59 | |||||
| Item 5 Efficacy of CTs | 1.00 | ||||||
| Item 6 Quality standards of CTs | 1.51 | 0.12 | 12.71 | <.001 | |||
| Item 7 Constituents and ingredients of CTs | 1.30 | 0.11 | 11.73 | <.001 | |||
| Item 8 Potential side effects of CTs | 1.13 | 0.11 | 10.77 | <.001 | |||
| F3 Suitability of CTs use | .84 | .52 | |||||
| Item 10 Purposes of CT use | 1.00 | .70 | |||||
| Item 11 Recommended dosage of CT use | 1.29 | 0.10 | 13.17 | <.001 | .89 | ||
| Item 12 Administration routes of CT use | 1.12 | 0.09 | 12.53 | <.001 | .83 | ||
| Item 13 Cost and affordability of CTs | 0.57 | 0.09 | 6.43 | <.001 | .39 | ||
| Item 14 Integration with conventional medicines | 0.95 | 0.09 | 11.18 | <.001 | .69 | ||
| F4 Support from health care professionals | .93 | .93 | |||||
| Item 15 Benefit-risk profile with HCP guidance | 1.00 | .98 | |||||
| Item 16 Support and advice from HCP | 0.93 | 0.06 | 16.47 | <.001 | .88 | ||
Note. SE=standard error; CR=critical ratio; AVE=average variance extracted; HCP=health care professional.